Key result
Direct oral anticoagulants significantly reduced the risk of venous thromboembolism recurrence compared to low molecular weight heparins in cancer patients (OR 0.68).
Why the study?
To evaluate the efficacy and safety of different DOACs compared with LMWHs in the treatment of VTE in cancer patients.
Do direct oral anticoagulants (DOACs) reduce recurrent venous thromboembolism compared to low molecular weight heparin (LMWHs) in cancer patients?
Population
Cancer patients with VTE across 18 studies (4 RCTs and 14 retrospective studies)
Comparison
Different DOACs vs LMWHs
Design
Systematic review and meta-analysis
Authors
Loading...
DOACs reduce recurrent VTE risk versus LMWH in cancer; reinforces first-line preference while leaving optimal agent selection open.
Meta-Analysis (n=7,319)
Do direct oral anticoagulants (DOACs) reduce recurrent venous thromboembolism compared to low molecular weight heparin (LMWHs) in cancer patients?
Odds Ratio: 0.68 (95% CI 0.57–0.8)
p-value: p=<0.001
In cancer patients with VTE, DOACs (particularly rivaroxaban) significantly reduce the risk of recurrent VTE and DVT compared to LMWHs, though they may increase the risk of clinically relevant non-major bleeding.
Song et al. (2020) conducted a meta-analysis in Venous thromboembolism in cancer patients (n=7,319). Direct oral anticoagulants (DOACs) vs. Low molecular weight heparin (LMWHs) was evaluated on Venous thromboembolism (VTE) recurrence (OR 0.68, 95% CI 0.57-0.8, p=<0.001). Direct oral anticoagulants significantly reduced the risk of venous thromboembolism recurrence compared to low molecular weight heparins in cancer patients (OR 0.68).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: